Browse the evidence

THDBH120 is a novel long-acting dual GIPR/GLP-1R agonist that has superior weight loss and metabolic improvement effects in rodents and mammals.

THDBH120 may be a promising treatment option for obesity and metabolic disorders.

Perturbation of gut-brain-pancreas communication contributes to metabolic disorders such as obesity and type 2 diabetes.

Recognizing these perturbations can guide therapeutic approaches for metabolic disorders.

The presence of metabolic abnormalities doubles event rates associated with obesity, with risk increasing with the number of metabolic abnormalities present.

Practitioners should consider the presence of metabolic abnormalities when assessing the risks of obesity in patients.

Metabolic parameters such as glycaemic, blood pressure, and lipid levels return to baseline within approximately 12 months after discontinuation.

Healthcare providers should monitor metabolic parameters closely after discontinuation of GLP-1RA therapy.

At 2.5 years, White individuals experienced significantly greater body weight loss than Black individuals: −7.1% versus −4.9%.

Practitioners should be aware of racial differences in weight loss outcomes when prescribing GLP-1RA therapy.

White individuals had significantly larger reductions in estimated glomerular filtration rate, systolic blood pressure, and HbA1c compared to Black individuals.

Healthcare providers should consider these differences in clinical outcomes when treating patients with GLP-1RA.

Emerging single-anastomosis variants demonstrate promising efficacy and improved gastrointestinal profiles.

Clinicians should consider these emerging techniques for patients seeking bariatric surgery.

There was no significant effect of either whey or soy protein supplementation on lean body mass (LBM).

Practitioners should note that protein supplementation may not significantly increase lean body mass.

A high protein diet (PRO) had a limited benefit on metabolic flexibility compared to a control diet (CON).

While a high protein diet is beneficial, its impact on metabolic flexibility may not be significant for older adults.

Protein supplementation during aerobic training did not significantly enhance cardiorespiratory fitness compared with an isocaloric placebo.

Practitioners should consider that protein supplementation may not provide additional benefits for improving cardiorespiratory fitness in stroke patients undergoing aerobic training.

There was no significant relationship between body fat mass changes and daily protein intake.

Practitioners should note that increasing protein intake may not affect body fat loss in older women.

Physical activity was associated with decreased fasting glucose, but this was not significant after adjusting for age and BMI.

While physical activity may lower fasting glucose, practitioners should consider age and BMI as significant factors.

Insulin resistance in aging is a multisystem phenomenon reflecting declining metabolic adaptability rather than a simple glucose disorder.

Practitioners should consider insulin resistance as a complex, systemic issue in older patients, not just a glucose management problem.

Women reporting usually irregular or very irregular menstrual cycles had an increased risk for nonfatal or fatal coronary heart disease (CHD) with age-adjusted relative risks of 1.25 and 1.67, respectively.

Practitioners should consider menstrual cycle regularity as a potential risk factor for cardiovascular disease in women.

Increased risks for coronary heart disease associated with prior cycle irregularity remained significant after adjustment for body mass index and several potential confounders.

Menstrual cycle irregularity should be evaluated in the context of other health metrics when assessing cardiovascular risk.

There was a nonsignificant increase in overall stroke risk associated with very irregular cycles (RR, 1.30; 95% CI = 0.97-1.74).

While there may be a link between menstrual irregularity and stroke risk, further investigation is needed due to the nonsignificant nature of the findings.

The real effect of carbohydrate was a slight reduction in power of 0.3%.

Carbohydrate supplementation may not provide the expected ergogenic benefit and could slightly reduce performance.

Asian Indians had a higher prevalence of noninsulin-dependent diabetes mellitus (NIDDM; 7.6% versus 1%; p < 0.0001).

Clinicians should monitor diabetes risk factors in this demographic.

Higher free fatty acid (FFA) concentrations during exercise do not significantly alter the relative contributions of carbohydrate or lipid oxidation to total energy expenditure after glucose feeding.

Practitioners can consider that elevated FFA levels during exercise do not significantly impact carbohydrate or lipid oxidation when glucose is ingested.

Increased availability of circulating free fatty acids (FFA) inhibits the rate of glycolysis in heart and resting skeletal muscle.

This suggests that practitioners should be aware of the inhibitory effects of elevated FFA on glycolysis during exercise.

The relative contributions of carbohydrate and lipid oxidation to total energy expenditure were different only during the first 30 min of exercise with elevated FFA levels.

Practitioners should note that the impact of elevated FFA on substrate utilization is time-dependent during prolonged exercise.

Pima Indians have lower sleep body core temperature (SLBCT) than Caucasians (36.45 +/- 0.10 vs 36.65 +/- 0.27 degrees C; P < 0.01).

Practitioners should consider ethnic differences in body temperature when assessing metabolic health.

Ethnic group accounted for 20% of the variance in sleep body core temperature (SLBCT) (P < 0.01).

Understanding ethnic differences in SLBCT can inform personalized health strategies.

The lower SLBCT in Pima Indians is not associated with a low metabolic rate.

Practitioners should note that lower body temperature does not necessarily indicate lower metabolism in Pima Indians.